drugset / Trial / NCT01263808

Cardiac Safety of Indacaterol

NCT01263808

Phase 1 Completed 404 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Timeline

Start
2008-04
Primary completion
2008-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Indacaterol Other / unclassified 300 ug Inhaled
Subject Indacaterol Other / unclassified 600 ug Inhaled
Comparator Moxifloxacin Small molecule 400 mg Oral